Subsequently, we confirmed that increased PD-L1 in the above drug-resistant cancer cells was functionally important to suppress CD3+ T cell proliferation, which supports the use of immunotherapy targeting the PD-L1/PD-1 axis to treat drug-resistant cancer cells. Here, CD274 is linked to cancer.